AKT1 and neoplasm: Moreover, in TNBC‐bearing animals, the administration of targeted anti‐Akt TNAs in combination with lipid nanoparticles led to reduced tumor sizes, decreased target protein expression, accelerated apoptotic responses and suppressed tumor cell proliferation in vivo.